Outcome of Liver Transplant Patients With Intraoperative-Detected Portal Vein Thrombosis: A Retrospective Cohort Study in Shiraz, Iran

2019 ◽  
Author(s):  
Kamran Bagheri Lankarani ◽  
◽  
Behnam Honarvar ◽  
Mozhgan Assadat Seif ◽  
Amir Anushiravani ◽  
...  
Keyword(s):  
Cohort Study ◽  
Portal Vein ◽  
Liver Transplant ◽  
Portal Vein Thrombosis ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Vein Thrombosis ◽  
Transplant Patients

scholarly journals Portal Vein Thrombosis in Adult Omani Patients: A Retrospective Cohort Study

2017 ◽  
Vol 32 (6) ◽  
pp. 522-527
Author(s):  
Khalid Al Hashmi ◽  
Lamya Al Aamri ◽  
Sulayma Al Lamki ◽  
Anil Pathare
Keyword(s):  
Cohort Study ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Vein Thrombosis

scholarly journals Pregnancy outcomes in women with Budd-Chiari syndrome or portal vein thrombosis - A multicentre retrospective cohort study

2021 ◽  
Author(s):  
Hanke Wiegers ◽  
Eva N. Hamulyák ◽  
Stefanie E. Damhuis ◽  
Jack R. Duuren ◽  
Sarwa Darwish Murad ◽  
...  
Keyword(s):  
Cohort Study ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Live Birth ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Budd Chiari Syndrome ◽  
Live Births ◽  
Vein Thrombosis ◽  
Chiari Syndrome

Objective: to evaluate current practice and outcomes of pregnancy in women previously diagnosed with Budd-Chiari syndrome and/or portal vein thrombosis, with and without concomitant portal hypertension. Design and setting: multicentre retrospective cohort study between 2008-2021 Population: Women who conceived in the predefined period after the diagnosis of Budd-Chiari syndrome and/or portal vein thrombosis Methods and main outcome measures: We collected data on diagnosis and clinical features. The primary outcomes were maternal mortality and live birth rate. Secondary outcomes included maternal, neonatal and obstetric complications. Results: Forty-five women (12 Budd-Chiari syndrome, 33 portal vein thrombosis; 76 pregnancies) were included. Underlying prothrombotic disorders were present in 23 of 45 women (51%). Thirty-eight women (84%) received low-molecular-weight heparin during pregnancy. Of 45 first pregnancies, 11 (24%) ended in pregnancy loss and 34 (76%) resulted in live birth of which 27 at term age (79% of live births and 60% of pregnancies). No maternal deaths were observed, one woman developed pulmonary embolism during pregnancy and two women (4%) had variceal bleeding requiring intervention. Conclusions: The high number of term live births (79%) and lower than expected risk of pregnancy-related maternal and neonatal morbidity in our cohort suggest that Budd-Chiari syndrome and/or portal vein thrombosis should not be considered as an absolute contra-indication for pregnancy. Individualized, nuanced counselling and a multidisciplinary pregnancy surveillance approach are essential in this patient population.

scholarly journals Clinical Impact of Portal Vein Thrombosis Prior to Liver Transplantation: A Retrospective Cohort Study

2017 ◽  
Vol 16 (2) ◽  
pp. 236-246 ◽  
Author(s):  
Constantine J. Karvellas ◽  
Filipe S. Cardoso ◽  
Marco Senzolo ◽  
Malcolm Wells ◽  
Mansour G. Alghanem ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Cohort Study ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Clinical Impact ◽  
Vein Thrombosis

scholarly journals Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases

2021 ◽  
Author(s):  
Maxime Taquet ◽  
Masud Husain ◽  
John R Geddes ◽  
Sierra Luciano ◽  
Paul Harrison
Keyword(s):  
Cohort Study ◽  
Portal Vein ◽  
Venous Thrombosis ◽  
Portal Vein Thrombosis ◽  
Retrospective Cohort Study ◽  
Cerebral Venous Thrombosis ◽  
Retrospective Cohort ◽  
Matched Cohort ◽  
Vein Thrombosis ◽  
Icd 10

Objectives: To estimate the absolute risk of cerebral venous thrombosis (CVT) and portal vein thrombosis (PVT) in the two weeks following a diagnosis of COVID-19, and to assess the relative risks (RR) compared to influenza or the administration of an mRNA vaccine against COVID-19. Design: Retrospective cohort study based on an electronic health records network Setting: Linked records between primary and secondary care centres within 59 healthcare organisations, primarily in the USA Participants: All patients with a confirmed diagnosis of COVID-19 between January 20, 2020 and March 25, 2021 were included (N=537,913, mean [SD] age: 46.2 [21.4] years; 54.9% females). Cohorts (matched for age, sex, and race) of participants diagnosed with influenza (N=392,424) or receiving the BNT162b2 or mRNA-1273 vaccine (N=366,869) were used for comparison. Main outcome measures: Diagnosis of CVT (ICD-10 code I67.6) or PVT (ICD-10 code I81) within 2 weeks after a diagnosis of COVID-19. Results: The incidence of CVT after COVID-19 diagnosis was 42.8 per million people (95% CI 28.5-64.2) including 35.3 per million (95% CI 22.6-55.2) first diagnoses. This was significantly higher than the CVT incidence in a matched cohort of patients with influenza (RR=3.83, 95% CI 1.56-9.41, P<0.001) and people who received an mRNA vaccine (RR=6.67, 95% CI 1.98-22.43, P<0.001). The incidence of PVT after COVID-19 diagnosis was 392.3 per million people (95% CI 342.8-448.9) including 175.0 per million (95% CI 143.0-214.1) first diagnoses. This was significantly higher than the PVT incidence in a matched cohort of patients with influenza (RR=1.39, 95% CI 1.06-1.83, P=0.02) and people who received an mRNA vaccine (RR=7.40, 95% CI 4.87-11.24, P<0.001). Mortality after CVT and PVT was 17.4% and 19.9% respectively. Conclusions: The incidence of CVT and PVT is significantly increased after COVID-19. The data highlight the risk of serious thrombotic events in COVID-19 and can help contextualize the risks and benefits of vaccination in this regard.

Natural history and clinical outcomes in patients with portal vein thrombosis by etiology: A retrospective cohort study

2019 ◽  
Vol 174 ◽  
pp. 137-140 ◽  
Author(s):  
Ana Acuna-Villaorduna ◽  
Vivy Tran ◽  
Jesus D. Gonzalez-Lugo ◽  
Elham Azimi-Nekoo ◽  
Henny H. Billett
Keyword(s):  
Cohort Study ◽  
Natural History ◽  
Portal Vein ◽  
Clinical Outcomes ◽  
Portal Vein Thrombosis ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Vein Thrombosis

scholarly journals Blood homocysteine levels are increased in hepatocellular carcinoma patients with portal vein thrombosis. A single centre retrospective cohort study

2018 ◽  
Vol 15 ◽  
pp. 60-65 ◽  
Author(s):  
Mariangela Malaguarnera ◽  
Vito Emanuele Catania ◽  
Antonio Maria Borzì ◽  
Stefano Malaguarnera ◽  
Roberto Madeddu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cohort Study ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Single Centre ◽  
Vein Thrombosis
Sign in / Sign up

Export Citation Format

Share Document